BioWorld Insight analyzes critical components of the biotech industry, from insights into which products are ahead or behind in a particular product space, the potential impact of new and pending regulatory rules and ideas for generating capital funding that is the lifeblood of the industry.
Every Monday – you'll have the behind-the-scenes analysis plus:
-
Our BioWorld Stock Report for U.S. publicly traded companies, listings for the London and Toronto stock exchanges, plus the 10 biggest gainers and losers for the week.
-
Find out who is ahead in niche markets, new and pending regulation, and ideas for generating the capital that is the lifeblood of the industry.
-
Insight examines business challenges – and potential solutions – that constantly face both industry giants and brand new start-ups.
Inside each issue – our exclusive charts and graphs to key biotech metrics – available nowhere else:
-
Clinical trial updates separated by indication (cancer, diabetes, etc.), plus FDA actions
-
Details of collaborations by biotech and pharma companies, deal modifications
-
manufacturing agreements
-
Public financing and private
-
Public offering performance by underwriters
-
FDA actions
BioWorld Insight – the in-depth financial companion to BioWorld Today for executives who demand the winning edge!